With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through our nearly 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|The Role of Germline Variants in Infant Leukemogenesis||Washington University / Margaret Ferris, MD/PhD||Young Investigator Grants||2019||Missouri|
|The role of immunogenetics in natural killer cell targeting of neuroblastoma||Memorial Sloan-Kettering Cancer Center / Katharine Hsu||Innovation Grants||2008||New York|
|The Role of Inherited MLL3 Single Nucleotide Variants and Fetal Epigenetic Programming in Infant Leukemogenesis||Washington University / Jeffrey Magee, MD/PhD||'A' Award Grants||2016||Missouri|
|The Role of Inhibition of Apoptosis by C/EBPalpha and C/EBPalpha oncoproteins in AML.||The Johns Hopkins University School of Medicine / Ido Paz-Priel, MD||Young Investigator Grants||2007||Maryland|
|The Role of Metabolism in MLL-AF9 Leukemia Initiation||Massachusetts General Hospital / Rushdia Yusuf||Young Investigator Grants||2010||Massachusetts|
|The Role of MiRNA Impairment in Wilms' Tumor Formation||University of Texas Southwestern Medical Center at Dallas / Kenneth Chen, MD||Young Investigator Grants||2016||Texas|
|The Role of MST1 in Non-canonical Hippo Signaling in Rhabdomyosarcoma||Duke University / Lisa Crose, Ph.D.||'A' Award Grants||2014||North Carolina|
|The Role of Mxi1 in the Modulation N-Myc Function in Neuroblastoma||Duke University / Michael Armstrong||Young Investigator Grants||2011||North Carolina|
|The role of NOTCH1 in T-cell acute lymphoblastic leukemia.||Columbia University Medical Center / Adolfo Ferrando||Bridge Grants||2012||New York|
|The role of OCT4 in self-renewal signaling and drug-resistance of childhood acute lymphoblastic leukemia||Children's Hospital Los Angeles / Markus Muschen||Innovation Grants||2008||California|